Category Archives: Psoriasis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2r4sgn/psoriasis_thought) has announced the addition of the "Psoriasis Thought Leader Panel #22 2012-04" report to their offering.

Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development.

The Panel Weighs in On:

- The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals.

- Increases and decreases in cardiovascular events associated with inhibitors of TNF, IL23, IL17 and IL12.

- Advantages/disadvantages of IL23/IL12 vs p19 inhibitors.

- Advantages of a pure IL12 inhibitor

- Advantages/drawbacks for broad vs subreceptor selective IL17 approaches.

- Combinations and immunosuppression

More:
Research and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of Persepectives from 6 Key Opinion Leaders

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2rw494/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Psoriasis" to their offering.

Psoriasis is a chronic inflammatory skin disease that, despite being non-life-threatening, has a tremendous impact on patients' quality of life. While topical therapies remain the mainstay of psoriasis treatment, the heightened awareness of psoriasis as a systemic disorder has led to an increased use of both conventional and biological systemic agents.

New entrants to the topicals arenaGalderma's vitamin D3 ointment Vectical (calcitriol) and Warner Chilcott's fixed-dose combination Taclonex (calcipotriene/betamethasone dipropionate)have increased the competition for patient share among topical agents owing to their more convenient administration (Taclonex) or steroid-sparing capacity (Vectical). In the moderate-to-severe psoriasis segment, the suboptimal side-effect profiles of the commonly used conventional systemics (i.e., methotrexate, cyclosporine) have opened the playing field to several biologics.

Among these, Amgen/Pfizer/Stiefel's TNF-a inhibitor Enbrel (etanercept) has historically captured the nearly all of biologics-eligible patients owing to dermatologists' comfort with its longstanding efficacy and safety record. However, Enbrel's positioning in the psoriasis treatment algorithm is becoming more vulnerable in light of increasing competition from newer entrants such as Abbott's Humira (adalimumab) and Janssen Biotech's interleukin-12 and -23 (IL-12/23) inhibitor Stelara (ustekinumab), both of which offer efficacy superior to that of Enbrel.

While Humira is establishing itself as a first-line biologic, Stelara's novel mechanism of action and limited long-term safety data have handicapped its uptake. Using patient-level claims data, this report determines the share of each currently marketed drug or class of drugs by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

Key Topics Covered:

1. Background

2. Key Findings for Newly Diagnosed Patients

3. Key Findings for Recently Treated Patients

Read more from the original source:
Research and Markets: Key Findings from Treatment Algorithms: Psoriasis

PETAH TIKVA, Israel, Oct. 9, 2012 /PRNewswire/ --Can-Fite BioPharma (TASE: CFBI; OTC: CANFY) announced today the continuation of patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating steadily over the 24-week treatment period. These clinical effect data corroborate the published Phase 2 study and confirm the dose selection, while the favorable safety profile of CF101 further supports its development for the systemic treatment of moderate-to-severe psoriasis. To allow the trial to meet its full objectives, the company therefore intends to complete patient enrollment for this Psoriasis Phase 2/3 clinical study comparing CF101-2 mg BID to placebo, as standalone therapy. The study will include approximately 300 patients overall and is currently conducted in 17 U.S., European and Israeli medical centers.

Psoriasis is a skin condition that affects 2% to 3% of the general population. The psoriasis therapeutic market is estimated at $3.5 billion annually and is dominated by biological drugs.

Can-Fite CEO Pnina Fishman, Ph.D., commented, "We are pleased to continue the clinical development plan of CF101, a small molecule orally bioavailable drug, based on its encouraging therapeutic index. CF101's anti-inflammatory effect, its well-defined mechanism of action, and the excellent safety profile, all suggest this drug is an attractive candidate for the treatment of psoriasis."

The company also announced that it has listed and begun trading of its American Depository Receipts (ADRs). Shares of the ADRs launched on October 2nd, 2012 on the over-the-counter (OTC) market under the symbol CANFY. The Company's ordinary shares trade on the Tel Aviv Stock Exchange under the symbol CFBI and each ADR share represents 50 ordinary shares.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase 2 clinical studies. CF101 is currently developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3). CF101 is also developed for ophthalmic indications including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis by OphthaliX (OPLI), a subsidiary of Can-Fite.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (CFBI.TA). American Depository Receipts of the company are traded on the over-the-counter market (CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman's scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a controlling interest (OPLI).

Contact:

KCSA Strategic Communications Jeff Corbin / Phil Carlson jcorbin@kcsa.com/ pcarlson@kcsa.com 212-896-1233

See the rest here:
Interim Analysis Supports Continuation of Can-Fite's Phase 2/3 Psoriasis Clinical Study with CF101

Psoriasis Free for Life by Katy Wilson now available as a holistic treatment for Psoriasis. More information can be found at http://bestguidesreviews.com/psoriasis-free-for-life/.

(PRWEB) October 08, 2012

The guide is an eBook created by Katy Wilson. She was a former psoriasis sufferer who turned out victorious against psoriasis after many years. This sad condition pushed her to explore various methods of curing psoriasis and her eBook can be termed as "a gift to all psoriasis sufferers". The main theme of the Psoriasis free for life guide is giving the body the needed ammo required to fight this auto-immune disease. The treatment detailed by the guide can also be done at home.

The Psoriasis Free for Life Guide explains the various causes of psoriasis and how it can be treated naturally. It dwells on all types of Psoriasis like:

It also includes bonus information as listed below:

Those who wish to treat psoriasis once and for all, and learn how to improve their overall health can take advantage of this eBook. The Psoriasis Free For life guide offers something special for psoriasis sufferers.

The Psoriasis Free for Life Guide is now available at http://bestguidesreviews.com/psoriasis-free-for-life/.

Admin BestGuidesReviews 917-72-00-66-8 Email Information

View original post here:
Psoriasis Free For Life Guide for Natural Psoriasis Treatment Now Available

By Paul G. Donohue, M.D. and Keith Roach, M.D.

October 06, 2012 12:00 AM

DEAR DRS. DONOHUE AND ROACH: Please give me new medicine information for psoriasis. I break out on my scalp very bad, and also on my face, back, chest and arms. It's slowly getting worse. Sometimes my skin is very itchy.

M.T.

Psoriasis is another illness you can blame the immune system for. It sends signals to the skin that prompt the lowest layer of cells to rise to the surface so quickly that they lack the maturity to protect the underlying layers of skin cells. Red patches covered with silvery scales result. Often, psoriatic patches itch. The scalp, elbows, knees and back are targets of psoriasis. The nails can develop pits that look like they're the result of a very slender ice pick.

The choice of medicine rests on where the patches are, how severe the outbreak is and the type of psoriasis a person has. Topical medicines are chosen to treat moderate to mild outbreaks. "Topical" indicates that the medicine is applied directly to the skin. Dovonex (a synthetic version of vitamin D) and Vectical ointment are two widely used topicals.

Stronger medicines belong to the cortisone family. Temovate and Diprolene are two examples.

Methotrexate and cyclosporine are two oral medicines that correct the immune system's excesses.

The newest psoriasis treatments are biological agents designed to rein in the wayward immune system. Their names include Enbrel, Remicade, Humira, Amevive and Stelara. They're administered in the doctor's office.

This information isn't of much use to you. All the above medicines require a prescription. Your best bet for conquering psoriasis is putting yourself in the care of a dermatologist, who can choose for you the medicines that will give you the best chance of controlling this often distressing skin illness.

Link:
Large menu of treatments for psoriasis

NEW YORK - People with chronic gum disease seem to be slightly more likely to develop the skin condition psoriasis, according to a new study.

Taiwanese researchers found that in a group of more than 230,000 people, those with gum disease were 54 percent more likely to get psoriasis over five years.

The study is among the first to investigate the link between the two conditions and doesn't necessarily mean gum disease can cause psoriasis.

"We don't know very much about what the risk factors are for chronic inflammatory diseases like psoriasis," said Dr. Joel Gelfand, a dermatologist at the University of Pennsylvania in Philadelphia, who was not involved in the new research.

"This study points in a potentially new direction for a potential risk factor thatin theorycould be modified and thus lower the risk of psoriasis in the future," he told Reuters Health. "That being said, this finding needs to be confirmed by more-rigorous, more-controlled studies to determine if the findings are real."

Link:
Gum disease linked to psoriasis: Taiwanese study

Psoriasis

NEW YORK (Reuters Health) - People with chronic gum disease seem to be slightly more likely to develop the skin condition psoriasis, according to a new study.

Taiwanese researchers found that in a group of more than 230,000 people, those with gum disease were 54 percent more likely to get psoriasis over five years.

The study is among the first to investigate the link between the two conditions and doesn't necessarily mean gum disease can cause psoriasis.

"We don't know very much about what the risk factors are for chronic inflammatory diseases like psoriasis," said Dr. Joel Gelfand, a dermatologist at the University of Pennsylvania in Philadelphia, who was not involved in the new research.

"This study points in a potentially new direction for a potential risk factor that - in theory - could be modified and thus lower the risk of psoriasis in the future," he told Reuters Health. "That being said, this finding needs to be confirmed by more-rigorous, more-controlled studies to determine if the findings are real."

Psoriasis is thought to be caused by a mistaken immune reaction directed at the body's own cells, leading to inflamed patches of red, scaly skin.

It's not the first time the condition has been linked to other health problems. Earlier this year, a study of people evaluated for heart disease found 84 percent of patients with psoriasis had coronary artery disease, compared to 75 percent of patients without the skin condition. (See Reuters Health article from January 10, 2012.)

Oral health has also been tied to other conditions, with two studies from this year finding links to heart disease and dementia. (See Reuters Health articles from April 19 and 21, 2012.)

But until now only one other study had looked at the link between psoriasis and chronic periodontitis, the advanced stage of the gum disease gingivitis.

Read more here:
Study: People with gum disease 54% more likely to develop psoriasis

NEW YORK (Reuters Health) - People with chronic gum disease seem to be slightly more likely to develop the skin condition psoriasis, according to a new study.

Taiwanese researchers found that in a group of more than 230,000 people, those with gum disease were 54 percent more likely to get psoriasis over five years.

The study is among the first to investigate the link between the two conditions and doesn't necessarily mean gum disease can cause psoriasis.

"We don't know very much about what the risk factors are for chronic inflammatory diseases like psoriasis," said Dr. Joel Gelfand, a dermatologist at the University of Pennsylvania in Philadelphia, who was not involved in the new research.

"This study points in a potentially new direction for a potential risk factor that - in theory - could be modified and thus lower the risk of psoriasis in the future," he told Reuters Health. "That being said, this finding needs to be confirmed by more-rigorous, more-controlled studies to determine if the findings are real."

Psoriasis is thought to be caused by a mistaken immune reaction directed at the body's own cells, leading to inflamed patches of red, scaly skin.

It's not the first time the condition has been linked to other health problems. Earlier this year, a study of people evaluated for heart disease found 84 percent of patients with psoriasis had coronary artery disease, compared to 75 percent of patients without the skin condition. (See Reuters Health article from January 10, 2012.)

Oral health has also been tied to other conditions, with two studies from this year finding links to heart disease and dementia. (See Reuters Health articles from April 19 and 21, 2012.)

But until now only one other study had looked at the link between psoriasis and chronic periodontitis, the advanced stage of the gum disease gingivitis.

For the new research, published in the British Journal of Dermatology, Dr. Joseph J. Keller from Taipei Medical University and his colleague turned to a database of Taiwan's national health system.

Read the original here:
Gum disease linked to psoriasis: study

Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced phase II data on its pipeline candidate, AIN457 (secukinumab), which is being developed for the treatment of moderate-to-severe plaque psoriasis on the hands, feet and nails.

Data from the double-blind phase II study showed that during the first month, weekly treatment with AIN457 helped reduce pain associated with moderate-to-severe plaque psoriasis on the hand and feet almost three times more than placebo (54.3% versus 19.2%).

Additionally, after 12 weeks of treatment with AIN457, 39% of the patients experienced either clear or minimal psoriasis. AIN457 was also found to reduce signs and symptoms of finger nail psoriasis in patients, when compared to placebo.

Further data presented at the European Academy of Dermatology and Venereology (:EADV), by Novartis, for the relief in signs and symptoms of moderate-to-severe plaque psoriasis showed that 12 weeks of treatment with AIN457, improved the quality of life (skin-related) in 25 times more patients in comparison to placebo.

Novartis stated in its press release that plaque psoriasis affects about 2% of the worlds population, out of which more than one third of patients suffer from its moderate-to-severe form.

Novartis is currently on track with pivotal phase III studies on AIN457 and expects data in 2013. The company is planning to file for regulatory approval once phase III results are available.

Novartis is also studying AIN457 in phase II trials for the treatment of multiple sclerosis.

We note already approved drugs for the treatment of moderate-to-severe plaque psoriasis include Johnson & Johnsons (JNJ) Stelara, Abbott Laboratories (ABT) Humira and Pfizer Inc. and Amgen Inc.s (PFE/AMGN) Enbrel.

Our Recommendation

Currently, we have a Neutral recommendation on Novartis. The company carries a Zacks #3 Rank (Hold rating) in the short run.

See the article here:
Novartis Progresses with AIN457

Research links psoriasis, Type 2 diabetes

While psoriasis and Type 2 diabetes seem like completely different medical problems, a new study of more than 100,000 psoriasis patients shows there is a link, and doctors are taking note.

Psoriasis is caused by an imbalance in the immune system, and it affects 2 percent to 4 percent of the population worldwide. The symptoms of psoriasis include red, scaly, itchy patches on the skin.

Mercy Medical Center dermatologist Dr. Janet Lin said psoriasis patients have several other health issues they need to keep their eye on, including a new one researchers are just learning about.

"Psoriasis is an independent risk factor for heart disease, for stroke, for obesity and for depression, and now they're even finding that if you have severe psoriasis, you're twice as likely to develop Type 2 diabetes," Lin said.

The study was done in the United Kingdom and published earlier this year in the "Archives of Dermatology."

"The most recent studies show there was an increased risk with the severity of the psoriasis. We think that's due to inflammation in the blood stream. The psoriasis releases some markers, increases inflammation and leads to insulin resistance and, eventually, Type 2 diabetes," said Dr. Amber Taylor, the director of the Diabetes Center at Mercy.

She said although the risk is fairly low for most psoriasis patients, they should still be screened.

Brenda Phipps said she's been suffering with psoriasis for 16 years.

"It takes a toll on my life, daily. I have my good days, and I have my bad days. It's very depressing," she said.

Visit link:
Study: Psoriasis patients more prone to diabetes